Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.526 CHF
−176.17 M CHF
97.95 M CHF
195.08 M
About Esperion Therapeutics, Inc.
Sector
CEO
Sheldon L. Koenig
Headquarters
Ann Arbor
Website
Founded
1998
FIGI
BBG00LVD9YR7
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
PFE5307022
Esperion Therapeutics, Inc. 4.0% 15-NOV-2025Yield to maturity
7.54%
Maturity date
Nov 15, 2025
Explore more bonds
Frequently Asked Questions
The current price of 0ET is 2.110 CHF — it has increased by 14.55% in the past 24 hours. Watch ESPERION THERAPEUT stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange ESPERION THERAPEUT stocks are traded under the ticker 0ET.
We've gathered analysts' opinions on ESPERION THERAPEUT future price: according to them, 0ET price has a max estimate of 14.29 CHF and a min estimate of 1.83 CHF. Watch 0ET chart and read a more detailed ESPERION THERAPEUT stock forecast: see what analysts think of ESPERION THERAPEUT and suggest that you do with its stocks.
0ET stock is 12.70% volatile and has beta coefficient of 3.14. Track ESPERION THERAPEUT stock price on the chart and check out the list of the most volatile stocks — is ESPERION THERAPEUT there?
Today ESPERION THERAPEUT has the market capitalization of 407.65 M, it has increased by 10.58% over the last week.
Yes, you can track ESPERION THERAPEUT financials in yearly and quarterly reports right on TradingView.
ESPERION THERAPEUT is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
0ET earnings for the last quarter are −0.13 CHF per share, whereas the estimation was −0.15 CHF resulting in a 14.42% surprise. The estimated earnings for the next quarter are −0.12 CHF per share. See more details about ESPERION THERAPEUT earnings.
ESPERION THERAPEUT revenue for the last quarter amounts to 43.75 M CHF, despite the estimated figure of 43.48 M CHF. In the next quarter, revenue is expected to reach 57.58 M CHF.
0ET net income for the last quarter is −25.02 M CHF, while the quarter before that showed −55.67 M CHF of net income which accounts for 55.06% change. Track more ESPERION THERAPEUT financial stats to get the full picture.
No, 0ET doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 240.00 employees. See our rating of the largest employees — is ESPERION THERAPEUT on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ESPERION THERAPEUT EBITDA is 25.08 M CHF, and current EBITDA margin is −133.58%. See more stats in ESPERION THERAPEUT financial statements.
Like other stocks, 0ET shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ESPERION THERAPEUT stock right from TradingView charts — choose your broker and connect to your account.